Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B trial

This publication has 35 references indexed in Scilit:

• Polychemotherapy for early breast cancer: an overview of the randomised trials
  The Lancet, 1998
• Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trial
  European Journal of Cancer, 1992
• “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
  European Journal of Cancer and Clinical Oncology, 1991
• ADJUVANT THERAPY WITH TAMOXIFEN IN OPERABLE BREAST CANCER: 10 year results of the Naples (GUN) study
  The Lancet, 1988
• Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF+ tamoxifen in a single centre
  Breast Cancer Research and Treatment, 1988
• Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer
  Breast Cancer Research and Treatment, 1985
• Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen
  European Journal of Cancer and Clinical Oncology, 1985
• BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES
  The Lancet, 1985
• Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer
  Breast Cancer Research and Treatment, 1983
• 1-Phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer.Lack of association of disease-free survival with depression of ovarian function
  Cancer, 1979